• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy.

作者信息

Nakamura Naokazu, Arai Yasuyuki, Kitawaki Toshio, Jo Tomoyasu, Mizumoto Chisaki, Kanda Junya, Nishikori Momoko, Yamashita Kouhei, Takaori-Kondo Akifumi

机构信息

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Department of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

出版信息

Br J Haematol. 2023 Jan;200(1):e1-e3. doi: 10.1111/bjh.18504. Epub 2022 Oct 11.

DOI:10.1111/bjh.18504
PMID:36220156
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10092564/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60bb/10092564/1009aba0ccbc/BJH-200-e1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60bb/10092564/1009aba0ccbc/BJH-200-e1-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60bb/10092564/1009aba0ccbc/BJH-200-e1-g001.jpg

相似文献

1
Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy.血清磷酸盐水平降低是预测嵌合抗原受体T细胞疗法中细胞因子释放综合征发生和严重程度的有用生物标志物。
Br J Haematol. 2023 Jan;200(1):e1-e3. doi: 10.1111/bjh.18504. Epub 2022 Oct 11.
2
Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.嵌合抗原受体 T 细胞治疗急性淋巴细胞白血病后细胞因子释放综合征中内皮细胞激活的预测作用。
J Cell Mol Med. 2021 Dec;25(24):11063-11074. doi: 10.1111/jcmm.17029. Epub 2021 Nov 3.
3
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.嵌合抗原受体 T 细胞治疗中细胞因子释放综合征的特征和危险因素。
Front Immunol. 2021 Feb 23;12:611366. doi: 10.3389/fimmu.2021.611366. eCollection 2021.
4
Continuous blood purification successfully treated severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy: A case report.连续血液净化成功治疗嵌合抗原受体T细胞疗法后严重细胞因子释放综合征及免疫效应细胞相关神经毒性综合征：一例报告
Pediatr Blood Cancer. 2022 Aug;69(8):e29563. doi: 10.1002/pbc.29563. Epub 2022 Jan 19.
5
Editorial: Understanding the Cytokine Release Syndrome: Toward Improving Cancer Immunotherapy.社论：理解细胞因子释放综合征：迈向改善癌症免疫治疗
Front Immunol. 2021 Mar 19;12:666703. doi: 10.3389/fimmu.2021.666703. eCollection 2021.
6
Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.病例报告：嵌合抗原受体 T 细胞治疗后急性淋巴细胞白血病患者出现局部细胞因子释放综合征：一种可能的模型、文献回顾与展望。
Front Immunol. 2021 Jul 19;12:707191. doi: 10.3389/fimmu.2021.707191. eCollection 2021.
7
Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.基于影像学的 CAR T 细胞治疗后毒性和反应模式评估。
Radiology. 2022 Feb;302(2):438-445. doi: 10.1148/radiol.2021210760. Epub 2021 Nov 9.
8
Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.细胞因子释放综合征是 CAR-T 细胞治疗后复发/难治性血液恶性肿瘤患者低白蛋白血症的独立危险因素。
BMC Cancer. 2023 Nov 2;23(1):1055. doi: 10.1186/s12885-023-11540-8.
9
Management Principles Associated With Cytokine Release Syndrome.与细胞因子释放综合征相关的管理原则。
Semin Oncol Nurs. 2019 Oct;35(5):150931. doi: 10.1016/j.soncn.2019.08.010. Epub 2019 Aug 31.
10
[Effect of early tocilizumab intervention on patients with cytokine release syndrome following chimeric antigen receptor T cell therapy].[托珠单抗早期干预对嵌合抗原受体T细胞治疗后细胞因子释放综合征患者的影响]
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):1022-1026. doi: 10.3760/cma.j.issn.0253-2727.2023.12.009.

引用本文的文献

1
Addition of Phosphorous and IL6 to m-EASIX Score Improves Detection of ICANS and CRS, as Well as CRS Progression.在改良EASIX评分中加入磷和白细胞介素-6可改善对免疫效应细胞相关神经毒性综合征（ICANS）和细胞因子释放综合征（CRS）的检测，以及CRS进展情况的检测。
Cancers (Basel). 2025 Mar 7;17(6):918. doi: 10.3390/cancers17060918.
2
Severe cases of local cytokine release syndrome (CRS); craniocervical edema soon after chimeric antigen T-cell (CAR-T) therapy.严重的局部细胞因子释放综合征（CRS）病例；嵌合抗原T细胞（CAR-T）治疗后不久出现的颅颈水肿。
Oxf Med Case Reports. 2025 Jan 18;2025(1):omae164. doi: 10.1093/omcr/omae164. eCollection 2025 Jan.
3

本文引用的文献

1
Contribution of phosphate and FGF23 to CKD progression.磷酸盐和 FGF23 对 CKD 进展的贡献。
Curr Opin Nephrol Hypertens. 2022 Jul 1;31(4):306-311. doi: 10.1097/MNH.0000000000000793. Epub 2022 Mar 11.
2
Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy.嵌合抗原受体 T 细胞治疗后 B 细胞血液系统恶性肿瘤患者细胞因子释放综合征的预后意义。
J Interferon Cytokine Res. 2021 Dec;41(12):469-476. doi: 10.1089/jir.2021.0057.
3
Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
Hypophosphatemia Correction Reduces ICANS Incidence and Duration in CAR T-cell Therapy: A Pooled Clinical Trial Analysis.
低磷血症纠正可降低 CAR-T 细胞治疗中 ICANS 的发生率和持续时间：一项汇总临床试验分析。
Cancer Res Commun. 2024 Oct 1;4(10):2589-2597. doi: 10.1158/2767-9764.CRC-24-0250.
4
Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy.利用红细胞分布宽度（RDW）作为可靠的生物标志物来预测嵌合抗原受体 T 细胞治疗后的治疗效果。
Clin Exp Med. 2024 May 21;24(1):105. doi: 10.1007/s10238-024-01373-5.
5
Early prediction of cytokine release syndrome by measuring phosphate and magnesium levels following chimeric antigen receptor T cell therapy.嵌合抗原受体T细胞疗法后通过测量磷酸盐和镁水平对细胞因子释放综合征进行早期预测。
Blood Cell Ther. 2023 Nov 25;6(4):129-134. doi: 10.31547/bct-2023-021.
6
Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy.低磷血症和输注前血小板减少作为CAR-T治疗后CRS和ICANS的生物标志物。
Bone Marrow Transplant. 2023 Nov;58(11):1267-1269. doi: 10.1038/s41409-023-02083-4. Epub 2023 Aug 14.
CD19 靶向 CAR-T 细胞疗法治疗复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和安全性：来自 JULIET、ZUMA-1 和 TRANSCEND 试验的观察结果。
Am J Hematol. 2021 Oct 1;96(10):1295-1312. doi: 10.1002/ajh.26301. Epub 2021 Aug 13.
4
Molecular and physical technologies for monitoring fluid and electrolyte imbalance: A focus on cancer population.用于监测液体和电解质失衡的分子和物理技术：以癌症人群为重点。
Clin Transl Med. 2021 Jun;11(6):e461. doi: 10.1002/ctm2.461.
5
Severe Electrolyte Disturbances Complicated by Seizures and Acute Kidney Injury Within 10 Days of Starting Indapamide.吲达帕胺起始治疗10天内出现严重电解质紊乱并伴有癫痫发作和急性肾损伤
Cureus. 2020 Nov 2;12(11):e11303. doi: 10.7759/cureus.11303.
6
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
7
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.CD19嵌合抗原受体修饰的T细胞疗法后严重细胞因子释放综合征的动力学及生物标志物
Blood. 2017 Nov 23;130(21):2295-2306. doi: 10.1182/blood-2017-06-793141. Epub 2017 Sep 18.